Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $124,318.48 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock in a transaction that occurred on Thursday, October 30th. The stock was sold at an average price of $1.43, for a total value of $124,318.48. Following the transaction, the insider owned 6,355,717 shares of the company’s stock, valued at $9,088,675.31. This represents a 1.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Stock Up 0.8%

HOWL stock opened at $1.22 on Thursday. The stock has a market capitalization of $55.79 million, a P/E ratio of -0.75 and a beta of 0.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.30 and a current ratio of 5.30. Werewolf Therapeutics, Inc. has a one year low of $0.60 and a one year high of $2.52. The company has a 50 day moving average price of $1.61 and a two-hundred day moving average price of $1.32.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Several institutional investors have recently made changes to their positions in HOWL. Vontobel Holding Ltd. purchased a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at $34,000. Charles Schwab Investment Management Inc. grew its stake in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock valued at $93,000 after buying an additional 23,852 shares during the period. Nuveen LLC purchased a new stake in Werewolf Therapeutics during the 1st quarter worth $71,000. MPM Asset Management LLC increased its holdings in Werewolf Therapeutics by 0.6% in the 1st quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares in the last quarter. Finally, MPM Bioimpact LLC increased its holdings in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares in the last quarter. 64.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on HOWL shares. Bank of America lowered their target price on shares of Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 16th. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.